InvestorsHub Logo
Followers 25
Posts 2991
Boards Moderated 2
Alias Born 10/18/2003

Re: terry hallinan post# 2823

Wednesday, 09/07/2005 7:17:17 PM

Wednesday, September 07, 2005 7:17:17 PM

Post# of 346000
Hello Pilgrim...

+++PPHM indicates that a TNT drug licensed to someone else has an approvable letter.

Really, who would that be? I think there is good chance Cotara may be approved for recurrent GBM should results from clinical studies the NABBT is enrolling endorsed such....

The only other approvable letter I can think of for TNT comes from the Peoples Republic of China, and that letter of approvable was generated years ago, I think two or three, for stage 3/4 lung cancer.

PPHM doesn't talk, they are still trying to figure it out.

The jewel is Tarvacin, yet, no one wants to talk about it at PPHM. No updates, no progress report, no one able to relay what the clinical roadmap is for calendar 2006. No real CEO for three years...etc. Tarvacin has a lot of potential to treat a multitude of enveloped viruses, and could be used in adjuvant course with chemo....

They just hired Premiere Oncology, Lee Rosen as one of the PIs for solid tumor cancer treatments, specialty is AA drugs...and company is incapable of announcing it...

Proxy is out, they want more shares, and more for options. I personally think they are keeping the PPS down so they can award more options to insiders and to retain a real CEO at these price levels. It's important for the CEO to have his options, compensation package aligned with the shareholders. I haven't ruled out a cheap sell-out given there is 200 million outstanding including options.

katie....
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News